Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

News

JDRF commits £1.3 million to investigate medication with the potential to delay kidney complications

Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.
Breakthrough T1D profile picture
Breakthrough T1D staff 13 October 2023

A hand holding a plastic model of a kidney

Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.

What’s the problem?

While kidney complications are common in people with type 1 diabetes, there are currently no approved medications to treat kidney disease in people with the condition.

What do the researchers want to find out?

Researchers at KCL and the Steno Diabetes Center Copenhagen will study the effects of sotagliflozin, a Sodium-Glucose Co-Transporter (SGLT) inhibitor, on people with type 1 and kidney disease.

What is an SGLT inhibitor?

SGLT inhibitors are drugs that work by blocking the protein SGLT-2 in the kidneys. This protein usually helps the kidneys reabsorb glucose from urine that would otherwise be lost when you urinate. As a result, when SGLT is blocked, more glucose ends up in the urine and is removed from the body, helping patients with type 2 diabetes manage their condition more effectively.

Over the past decade, SGLT inhibitors have proven to be effective for people with type 2 diabetes and people without diabetes, reducing the progression of kidney disease and heart disease.

However, there has been a lack of research exploring SGLT inhibitors as a treatment for people with kidney disease and type 1 diabetes. This award from JDRF will allow the investigators to find out how this type of therapy works in type 1.

How will the researchers find out if these drugs work in people with type 1?

A trial will take place at the Steno Center in Copenhagen and at KCL, where clinicians will recruit participants from across southeast London. Researchers will investigate how the drug, sotagliflozin, works on the kidneys using magnetic resonance imaging (MRI), which can provide a measure of kidney function and oxygen content, as well as measure a potential benefit on the heart.

“In the past decade we have seen amazing results in the treatment of diabetes complications with the drug class SGLT inhibitors. They have reduced progression of kidney and heart disease in people with type 2 diabetes and improve glycemic control in type 1 diabetes, but it is not clear how they work,” said Peter Rossing, M.D., Head of Complications Research At Steno Diabetes Center Copenhagen and lead investigator for this study. “Understanding how SGLT inhibitors work is important for the optimal use of these drugs. With no current approved medication for treatment of kidney disease in people with type 1 diabetes, our study could help pave the way if a benefit is demonstrated.”

Why is it important that this research includes people from different ethnic backgrounds?

Recent work from KCL highlighted that African-Caribbean people with type 1 diabetes had a higher and faster risk of kidney disease progression, which was independent of traditional risk factors.

During this trial, researchers at KCL will have the additional aim of evaluating whether there are potential biological differences between African-Caribbean and non-African-Caribbean people in kidney baseline measures as well as in treatment responses.

Janaka Karalliedde, Clinical Reader in Diabetes and Cardiovascular Disease at King’s College London, says: “To date there are no clinical trials in people with type 1 diabetes of African-Carribean heritage who are often at higher risk of kidney complications of diabetes. This landmark study is a really important first milestone in this area and we are delighted to be involved as there is huge potential for new treatments that will make real clinical impact in an under-researched area of type 1 diabetes.”

Why has Breakthrough T1D UK chosen to fund this research?

Rachel Connor, Director of Research Partnerships at JDRF UK said: “We are delighted to provide funding for this much-needed clinical trial which will test whether SGLT-2 inhibitors can slow the progression of kidney disease in people with type 1 diabetes. Kidney disease is challenging to live with. Its treatments are demanding, it limits people’s lifestyles and it’s emotionally draining; and yet there are currently no approved medicines for people with type 1 diabetes and kidney disease.

“If this study shows that SGLT-2 inhibitors can effectively delay kidney complications for people with type 1, the results could be put into practice very swiftly, benefiting the entire type 1 diabetes community, enabling people to live longer, healthier and happier lives.”

You may also be interested in

Read more
Kidneys

Find out more about kidney complications

People with type 1 diabetes are at a higher risk of developing kidney problems, called nephropathy.<br />

Read more
A hand holding a plastic model of a kidney

Ethnicity as a risk factor in developing kidney disease

New research confirms for the first time that ethnicity is a risk factor for developing kidney disease in people with type 1 diabetes.

Related news

Read more
A young woman wearing a continuous glucose monitor looks on to a man scanning his sensor.
News
29 October 2024

New report calls for more equal access to type 1 diabetes technology

Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.

Read more
A researcher sits in a lab beside screening samples and lab equipment for early detection of type 1 diabetes.
Research
24 June 2024

New guidance sets out how to support people with early-stage type 1 diabetes

New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.

Read more
Would I Lie To You? Banner
Advocacy
1 February 2024

Our letter to the producers of Would I Lie to You?

We wrote to the producers of the hit BBC show after they broadcast jokes about type 1 diabetes.

Read more
A doctor talking to a young woman holding a pen
Policy and advocacy
23 January 2024

Parliamentary Inquiry calls for urgent action on type 1 and disordered eating

Parliamentary Inquiry chaired by our Global Health Ambassador, Rt. Hon Theresa May MP and Sir George Howarth MP, highlights the risks of type 1 diabetes-related eating disorders (T1DE).

Connect with us on social